Exploring MECHANISM of early and late vascular responses of ULTIMASTER sirolimus-eluting stent for treatment of ST-elevation Acute Myocardial Infarctio
- Conditions
- Coronary Artery Disease
- Registration Number
- JPRN-UMIN000021549
- Lead Sponsor
- Iwate Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Not provided
1) Patients who are judged incapable of undergoing clinical follow-up 12 months after PCI (Consider also the location of patients' residences) 2) Lack of specific findings of ACS by angiography (Left to the operator's decision.) 3) Shock 4) The culprit lesion is the left main coronary trunk 5) Lesion with the reference vessel diameter less than 2.0mm or larger than 4.5mm by visual evaluation. 6) AMI due to stent thrombosis at prior stented segment. 7) Chronic renal failure with serum creatinine level not less than 2.0mg/dl on hospital visit 8) Patients on hemodialysis 9) Cancer patients whose vital prognosis is expected to be within 2 years. 10) Surgery that requires discontinuation of the antiplatelet agent is scheduled within 3 months. 11) Female patient plan to became pregnant or during pregnancy. 12) Patients who experienced adverse reaction to aspirin or clopidogrel (this shall not apply for patients in whom safety of ticlopidine is confirmed)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The percentage of stent strut coverage by OFDI at 1 month (To observe temporal course from the early stage, the rate of stent-strut coverage in the 3-month arm will also be evaluated in a complementary manner, separately from the 1-month arm.)
- Secondary Outcome Measures
Name Time Method